Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients (NCT05899608)
A Randomized, Double-blind, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer (HARMONi-3)
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.
Who can join: Review the eligibility criteria below.
Location: Banner University Medical Center — Phoenix, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (260 Sites)
Showing the first 25 of 260 sites.
- Banner University Medical Center — Phoenix, Arizona
- TMC Healthcare — Tucson, Arizona
- Genesis Cancer and Blood Institute — Hot Springs, Arkansas
- University of Arkansas — Little Rock, Arkansas
- LA Cancer Network — Anaheim, California
- The Oncology Institute of Hope & Innovation — Cerritos, California
- University of Southern California (USC) — Los Angeles, California
- Cedar Sinai Medical Center — Los Angeles, California
- Valkyrie Clinical Trials — Los Angeles, California
- Sutter Institute for Medical Research — Sacramento, California
- UC Davis Medical Center — Sacramento, California
- University of California Los Angeles (UCLA) — Santa Monica, California
- Providence Medical Foundation — Santa Rosa, California
- Kaiser Permanente — Vallejo, California
- Rocky Mountain Cancer — Lone Tree, Colorado
- Banner MD Anderson Cancer Center at North Colorado Medical Center — Loveland, Colorado
- Hartford Hospital — Hartford, Connecticut
- Yale University — New Haven, Connecticut
- Florida Cancer Specialists & Research Institute (FCS)-East — Fort Myers, Florida
- BioResearch Partner- Hialeah Hospital — Hialeah, Florida
- Memorial Healthcare System — Hollywood, Florida
- Mayo Clinic — Jacksonville, Florida
- Cancer Specialists of North Florida — Jacksonville, Florida
- Ocala Oncology — Ocala, Florida
- Cancer Care of Brevard — Palm Bay, Florida
📞 Contact the Study Coordinator
Phone: (833) 256-0522
Email: medicalinformation@smmttx.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-Small Cell Lung Cancer
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations — Birmingham, Alabama
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) — La Jolla, California
- PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer — Houston, Texas
- Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer — Renton, Washington
- Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer — Boston, Massachusetts
- Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) — Chandler, Arizona
Explore by condition: All Non-Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.